Peripheral-central inflammatory crosstalk in Alzheimer's disease: immunometabolic functions of circulating soluble metabolites under dynamic blood-brain barrier states
This narrative review proposes that low-molecular-weight circulating soluble metabolites (<500 Da) cross an intact blood-brain barrier and contribute to early neuroinflammation in Alzheimer's disease, but provides no original empirical data to support causality.
| Population | Patients with Alzheimer's disease or mild cognitive impairment, and relevant preclinical models |
|---|---|
| Intervention | Low-molecular-weight circulating soluble metabolites (<500 Da): peripheral immune-derived mediators, gut microbiota-derived metabolites, and host systemic metabolic intermediates |
| Comparator | Six other canonical peripheral-central crosstalk mechanisms (cellular infiltration, cytokine transcytosis, circumventricular organs, lipophilic hormones, vagal reflex, immune exosomes) |
| Outcome | Soluble metabolite transport across intact BBB; mTOR-NLRP3 inflammasome activation by peripheral metabolites; Histone epigenetic remodelling by circulating metabolites; Mitochondrial dysfunction mediated by peripheral metabolites in neurons; Potential of circulating metabolites as ultra-early AD biomarkers |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Soluble metabolite transport across intact BBB | narrative synthesis only; in the quantitative effect measure reported | — | Very low | — | |
| mTOR-NLRP3 inflammasome activation by peripheral metabolites | narrative synthesis only; in the quantitative effect measure reported | — | Very low | — | |
| Histone epigenetic remodelling by circulating metabolites | narrative synthesis only; in the quantitative effect measure reported | — | Very low | — | |
| Mitochondrial dysfunction mediated by peripheral metabolites in neurons | narrative synthesis only; in the quantitative effect measure reported | — | Very low | — | |
| Potential of circulating metabolites as ultra-early AD biomarkers | narrative synthesis only; in the quantitative effect measure reported | — | Very low | — |
Context
Peripheral immunometabolic dysregulation is proposed as a contributor to chronic neuroinflammation in AD, yet trans-barrier signaling mechanisms at prodromal stages remain poorly characterised. Most prior models emphasised cellular infiltration and macromolecular leakage, both requiring structural BBB disruption. This review positions soluble metabolites as early mediators capable of acting before such disruption occurs.
What the study showed
The review argues that metabolites <500 Da (e.g., lactate, succinate, short-chain fatty acids) use carrier-mediated transport and passive diffusion to cross the intact BBB, whereas the other six pathways require structural disruption or are anatomically restricted. The authors propose that these metabolites activate convergent intracellular cascades — mitochondrial oxidative stress, mTOR-NLRP3 inflammasome activation, and histone epigenetic remodelling — sustaining silent neuroinflammation during the prodromal stage. No primary data, effect sizes, or confidence intervals are presented; all claims derive from narrative synthesis of secondary literature. The authors explicitly acknowledge that the proposed links have not been validated in human cohorts.
How it was done
Narrative review (non-systematic, no registered PROSPERO protocol, no explicit search strategy, no formal inclusion/exclusion criteria). No primary data collection, randomisation, control group, or statistical analysis. Synthesis integrates in vitro studies, animal models, and human cohorts without differentiating evidential weight by outcome.
Effect magnitude
No effect sizes quantified; no 95% CIs reported. The review is descriptive and conceptual, with no aggregated data.
Risk of bias
Narrative review without systematic methodology (AMSTAR-2 not formally applicable but expected for scoping reviews): no reproducible search strategy, no defined eligibility criteria, and no risk-of-bias assessment of primary studies. Synthesis conflates evidence from in vitro, animal, and human models without quality stratification. Authors acknowledge that proposed causal links between peripheral metabolites and early neuroinflammation in human AD have not been confirmed in clinical trials. High risk of confirmation bias in literature selection.
What this study does NOT prove
This study does not prove that circulating soluble metabolites cause neuroinflammation or accelerate AD progression in humans. It establishes neither statistical association nor causality between any specific metabolite and clinical outcomes in AD.
In clinical practice
No clinical practice recommendation is supported by this review. Clinicians should treat the content as a hypothesis-generating conceptual framework, not as a guide for diagnostic or therapeutic decision-making. Monitoring of peripheral metabolites in AD remains investigational.
Limitations
Narrative review without systematic methodology (AMSTAR-2 not formally applicable but expected for scoping reviews): no reproducible search strategy, no defined eligibility criteria, and no risk-of-bias assessment of primary studies. Synthesis conflates evidence from in vitro, animal, and human models without quality stratification. Authors acknowledge that proposed causal links between peripheral metabolites and early neuroinflammation in human AD have not been confirmed in clinical trials. High risk of confirmation bias in literature selection.
What is still missing
Prospective clinical trials and longitudinal cohort studies measuring specific circulating metabolites at prodromal AD stages with validated neuroinflammatory outcomes (e.g., neuroinflammation PET, CSF biomarkers). Interventional studies modulating peripheral metabolites and assessing effects on cognitive progression are required to test causality.
Technical appendix
Version history
- 1.0 · 2026-09-18 — Auto-generated under Evidence Standard v1.0